Esperion Therapeutics (ESPR) Tops Q2 EPS by $2.61, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020 4:05 PM EDT Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue
 Strong Capital Position with over $300 Million in Cash
 Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage
 Consistently High Month-Over-Month Growth for New Medicines With Acceleration in Second Half
 Conference Call and Webcast on August 10 at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results... More
